376 related articles for article (PubMed ID: 15363455)
1. Modeling of p38 mitogen-activated protein kinase inhibitors using the Catalyst HypoGen and k-nearest neighbor QSAR methods.
Xiao Z; Varma S; Xiao YD; Tropsha A
J Mol Graph Model; 2004 Oct; 23(2):129-38. PubMed ID: 15363455
[TBL] [Abstract][Full Text] [Related]
2. Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation.
Tang H; Wang XS; Huang XP; Roth BL; Butler KV; Kozikowski AP; Jung M; Tropsha A
J Chem Inf Model; 2009 Feb; 49(2):461-76. PubMed ID: 19182860
[TBL] [Abstract][Full Text] [Related]
3. Application of validated QSAR models of D1 dopaminergic antagonists for database mining.
Oloff S; Mailman RB; Tropsha A
J Med Chem; 2005 Nov; 48(23):7322-32. PubMed ID: 16279792
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors.
Sarma R; Sinha S; Ravikumar M; Kishore Kumar M; Mahmood SK
Eur J Med Chem; 2008 Dec; 43(12):2870-6. PubMed ID: 18406015
[TBL] [Abstract][Full Text] [Related]
5. Application of predictive QSAR models to database mining: identification and experimental validation of novel anticonvulsant compounds.
Shen M; Béguin C; Golbraikh A; Stables JP; Kohn H; Tropsha A
J Med Chem; 2004 Apr; 47(9):2356-64. PubMed ID: 15084134
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
Parenti MD; Pacchioni S; Ferrari AM; Rastelli G
J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997
[TBL] [Abstract][Full Text] [Related]
7. A novel 3D-QSAR comparative molecular field analysis (CoMFA) model of imidazole and quinazolinone functionalized p38 MAP kinase inhibitors.
Sperandio da Silva GM; Sant'Anna CM; Barreiro EJ
Bioorg Med Chem; 2004 Jun; 12(12):3159-66. PubMed ID: 15158784
[TBL] [Abstract][Full Text] [Related]
8. kappa Nearest neighbors QSAR modeling as a variational problem: theory and applications.
Itskowitz P; Tropsha A
J Chem Inf Model; 2005; 45(3):777-85. PubMed ID: 15921467
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial QSAR modeling of specificity and subtype selectivity of ligands binding to serotonin receptors 5HT1E and 5HT1F.
Wang XS; Tang H; Golbraikh A; Tropsha A
J Chem Inf Model; 2008 May; 48(5):997-1013. PubMed ID: 18470978
[TBL] [Abstract][Full Text] [Related]
10. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.
Ravindra GK; Achaiah G; Sastry GN
Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of k-nearest-neighbor QSPR models of metabolic stability of drug candidates.
Shen M; Xiao Y; Golbraikh A; Gombar VK; Tropsha A
J Med Chem; 2003 Jul; 46(14):3013-20. PubMed ID: 12825940
[TBL] [Abstract][Full Text] [Related]
12. QSAR modeling using chirality descriptors derived from molecular topology.
Golbraikh A; Tropsha A
J Chem Inf Comput Sci; 2003; 43(1):144-54. PubMed ID: 12546547
[TBL] [Abstract][Full Text] [Related]
13. Quantitative structure-activity relationship modeling of dopamine D(1) antagonists using comparative molecular field analysis, genetic algorithms-partial least-squares, and K nearest neighbor methods.
Hoffman B; Cho SJ; Zheng W; Wyrick S; Nichols DE; Mailman RB; Tropsha A
J Med Chem; 1999 Aug; 42(17):3217-26. PubMed ID: 10464009
[TBL] [Abstract][Full Text] [Related]
14. Generation and validation of the first predictive pharmacophore model for cyclin-dependent kinase 9 inhibitors.
Fang C; Xiao Z; Guo Z
J Mol Graph Model; 2011 Apr; 29(6):800-8. PubMed ID: 21333571
[TBL] [Abstract][Full Text] [Related]
15. QSAR modeling of human serum protein binding with several modeling techniques utilizing structure-information representation.
Votano JR; Parham M; Hall LM; Hall LH; Kier LB; Oloff S; Tropsha A
J Med Chem; 2006 Nov; 49(24):7169-81. PubMed ID: 17125269
[TBL] [Abstract][Full Text] [Related]
16. CoMFA and docking studies on triazolopyridine oxazole derivatives as p38 MAP kinase inhibitors.
Shashi Nayana MR; Sekhar YN; Siva Kumari N; Mahmood SK; Ravikumar M
Eur J Med Chem; 2008 Jun; 43(6):1261-9. PubMed ID: 17825954
[TBL] [Abstract][Full Text] [Related]
17. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
Pandey G; Saxena AK
J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
[TBL] [Abstract][Full Text] [Related]
18. Structural analysis of carboline derivatives as inhibitors of MAPKAP K2 using 3D QSAR and docking studies.
Nayana RS; Bommisetty SK; Singh K; Bairy SK; Nunna S; Pramod A; Muttineni R
J Chem Inf Model; 2009 Jan; 49(1):53-67. PubMed ID: 19119997
[TBL] [Abstract][Full Text] [Related]
19. Does rational selection of training and test sets improve the outcome of QSAR modeling?
Martin TM; Harten P; Young DM; Muratov EN; Golbraikh A; Zhu H; Tropsha A
J Chem Inf Model; 2012 Oct; 52(10):2570-8. PubMed ID: 23030316
[TBL] [Abstract][Full Text] [Related]
20. LQTA-QSAR: a new 4D-QSAR methodology.
Martins JP; Barbosa EG; Pasqualoto KF; Ferreira MM
J Chem Inf Model; 2009 Jun; 49(6):1428-36. PubMed ID: 19422246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
